Search

everythinglearnresearchcommunity

for

Search:↓

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

Scalp cooling and low-power light therapy show promise in reducing chemotherapy-induced hair loss but need more research.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Older adults have a high rate of skin cancers like basal cell carcinoma and melanoma, mainly due to UV exposure and age.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Cooling the scalp below 22°C before and during chemotherapy can help prevent hair loss.

Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Tamoxifen caused hair loss in a 52-year-old woman.

Higher DHT in male baldness may protect against prostate cancer.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Septin4 helps kill colon cancer cells by working with the protein BAX.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Using radiation to make mice's hair turn gray helps study and find ways to prevent or reverse hair graying.

PLD is an effective and safer alternative for treating breast cancer.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Hair and nail changes can indicate health issues, including cancer and side effects from cancer treatments.